QURE — uniQure N.V.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1590560 ·
Netherlands
Last close
$20.78
Market Cap
$1.46B
52W High
$51.72
52W Low
$8.73
ADV30
1,912,946
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 5,196,000 | 4,960,000 | -53,402,000 | -61,217,000 | 940,551,000 | 98,442,000 | 645,898,000 |
| Jun 2026 | 5,841,000 | 5,491,000 | -44,676,000 | -81,059,000 | 985,103,000 | 413,027,000 | 661,053,000 |
| Mar 2026 | 3,562,000 | 3,343,000 | -44,269,000 | -53,535,000 | 778,706,000 | 139,994,000 | 629,363,000 |
| Dec 2025 | 5,568,000 | 5,133,000 | -51,494,000 | -37,086,000 | 824,908,000 | 80,240,000 | 626,007,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-192,215,000
Investing CF
$-558,282,000
Financing CF
$253,672,000
CapEx
$-742,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.33
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,524,747,000
Inventory
—
Receivables
$4,804,000
ST Investments
$570,021,000
EBIT TTM
$-176,262,000
Pretax Income TTM
$-233,808,000
Interest Exp TTM
$57,546,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$20,167,000
EBITDA
$-184,168,000
Free Cash Flow
$-167,192,128
Enterprise Value
$1,413,188,224
Total Cash
$668,462,976
Total Debt
$559,638,016
Shares Out
70,138,860
Trailing EPS
$-3.51
Book Value
$4.21
ROE
-89.0%
ROA
-13.7%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 16,098,000 | -187,827,000 | -198,971,000 | 824,908,000 | 626,007,000 | 198,901,000 | -177,963,000 |
| Dec 2024 | 27,119,000 | -182,180,000 | -239,556,000 | 556,536,000 | 563,288,000 | -6,752,000 | -182,728,000 |
| Dec 2023 | 15,843,000 | -282,486,000 | -308,478,000 | 831,689,000 | 624,019,000 | 207,670,000 | -145,929,000 |
| Dec 2022 | 106,483,000 | -144,246,000 | -126,789,000 | 704,964,000 | 228,955,000 | 476,009,000 | -145,060,000 |
TTM Snapshot
Revenues TTM
$18,672,000
NetIncome TTM
$-252,209,000
OpCashFlow TTM
—
Assets (Latest)
$985,103,000
Forward EPS
$-3.20
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $22.00 · spot: $20.30 · call volume: 3,172 · put volume: 1,386
Expected Move to 2026-12-18:
±$5.30
(26.11%) —
implied range
$15.00 –
$25.60
· ATM straddle on $20.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PCRX | Pacira BioSciences, Inc. | $1.46B | $36.48 | — |
| URGN | UroGen Pharma Ltd. | $1.47B | $29.87 | — |
| KRSA | Korsana Biosciences, Inc. | $1.48B | $32.50 | — |
| RAPP | Rapport Therapeutics, Inc. | $1.41B | $23.76 | — |
| DMRA | Damora Therapeutics, Inc. | $1.40B | $22.56 | — |
News headlines (Yahoo Finance, 1h cache)
uniQure CEO Defends Huntington’s Therapy Data, Sees Opportunity Ahead of FDA Decision
2026-11-13 23:12 · Yahoo
QURE Stock Rallies 17.5% in a Month: What Should Investors Do Now?
2026-11-13 17:16 · Yahoo
uniQure Prepares for Potential FDA Panel on Huntington’s Gene Therapy After Priority Review Nod
2026-11-13 12:14 · Yahoo
Is uniQure (QURE) Priced Beyond Its Book Value Support?
2026-11-13 03:20 · Yahoo
Reduced Loss And Higher Revenue Could Shift The Case For uniQure Stock
2026-11-06 02:16 · Yahoo
uniQure N.V. Q3 2026 Earnings Call Summary
2026-11-04 22:55 · Yahoo
uniQure (QURE) Q3 2026 Earnings Call Transcript
2026-11-04 19:45 · Yahoo
uniQure Q3 Earnings Call Highlights
2026-11-04 19:14 · Yahoo
uniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates
2026-11-04 12:55 · Yahoo
UniQure: Q3 Earnings Snapshot
2026-11-04 12:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.